Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Dow
Medtronic
Healthtrust
Chubb
Cantor Fitzgerald
Fish and Richardson
Daiichi Sankyo
Argus Health
Fuji

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 015874

« Back to Dashboard

NDA 015874 describes ALUPENT, which is a drug marketed by Boehringer Ingelheim and is included in five NDAs. Additional details are available on the ALUPENT profile page.

The generic ingredient in ALUPENT is metaproterenol sulfate. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the metaproterenol sulfate profile page.
Summary for 015874
Tradename:ALUPENT
Applicant:Boehringer Ingelheim
Ingredient:metaproterenol sulfate
Patents:0
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength20MG
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength10MG
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Expired US Patents for NDA 015874

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim ALUPENT metaproterenol sulfate TABLET;ORAL 015874-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim ALUPENT metaproterenol sulfate TABLET;ORAL 015874-002 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
McKinsey
Accenture
Daiichi Sankyo
Moodys
Citi
AstraZeneca
Fuji
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot